Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use GAMIFANT safely and effectively. See full prescribing information for GAMIFANT. GAMIFANT® (emapalumab-lzsg) injection, for intravenous use Initial U.S. Approval: 2018
Medication labelWhy this: Advisory · dailymed-prescription
GAMIFANT is indicated for the treatment of: adult and pediatric patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance with conventional HLH therapy. adult and pediatric patients with HLH/macrophage activation syndrome (MAS) in known or suspected Still’s disease, including systemic Juvenile Idiopathic Arthritis (sJIA), with an inadequate response or intolerance to glucocorticoids, or with recurrent MAS.
- generic_name
- emapalumab-lzsg
- product_names
- emapalumab-lzsg
- ndc
- 66658-501, 66658-501-01, 66658-505, 66658-505-01, 66658-510, 66658-510-01, 66658-522, 66658-522-01, 66658-523, 66658-523-01, 66658-524, 66658-524-01, 66658-525, 66658-525-01
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en